4 2021 с обл

ПОВОЛЖСКИЙ
ОНКОЛОГИЧЕСКИЙ
ВЕСТНИК
and survival // Clin. Cancer Res. — 2009. — 15. —
P. 4742-4749.
38. Zhou L., Liu X.D., Sun M. et al. Targeting MET and
AXL overcomes resistance to sunitinib therapy in
renal cell carcinoma // Oncogene. — 2016. — 35. —
P. 2687-2697.
39. Yamamoto Y., Matsui J., Matsushima T. et al. Lenvatinib,
an angiogenesis inhibitor targeting VEGFR/FGFR,
shows broad antitumor activity in human tumor
xenograft models associated with microvessel density
and pericyte coverage // Vasc Cell. — 2014. — 6. —
P. 18.
40. Matsuki M., Adachi Y., Ozawa Y. et al. Targeting of tumor
growth and angiogenesis underlies the enhanced
antitumor activity of lenvatinib in combination
with everolimus // Cancer Sci. — 2017. — 108. —
P. 763-771.
41. Ohaegbulam K.C., Assal A., Lazar-Molnar E. et al.
Human cancer immunotherapy with antibodies to
the PD-1 and PD-L1 pathway // Trends Mol Med. —
2015. — 21. — P. 24-33.
42. Nizar M. Tannir, Sumanta K. Pal, Michael B. Atkins,
Second Line Treatment Landscape for Renal
Cell Carcinoma: A Comprehensive Review // The
Oncologist. — May 2018. — Vol. 23, Is. 5. — P. 540-555.
https://doi.org/10.1634/theoncologist.2017-0534.
43. Motzer R.J., Escudier B., Oudard S. et al. Efficacy
of everolimus in advanced renal cell carcinoma:
A double-blind, randomised, placebo-controlled
phase III trial // Lancet. — 2008. — 372. — P. 449-456.
44. Rini B.I., Escudier B., Tomczak P. et al. Comparative
effectiveness of axitinib versus sorafenib in advanced
renal cell carcinoma (AXIS): A randomized phase 3 tria //
Lancet. — 2011. — 378. — P. 1931-1939.
45. Motzer R.J., Escudier B., McDermott D.F. et al.
Nivolumab versus everolimus in advanced renalcell
carcinoma // N. Engl. J. Med. — 2015. — 373. —
P. 1803-1813.
46. Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib
versus everolimus in advanced renal-cell carcinoma //
N. Engl. J. Med. — 2015. — 373. — P. 1814-1823.
47. Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib,
everolimus, and the combination in patients with
metastatic renal cell carcinoma: A randomised,
phase 2, open-label, multicentre trial // Lancet Oncol.
— 2015. — 16. — P. 1473-1482.
48. Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of
everolimus for metastatic renal cell carcinoma: Final
results and analysis of prognostic factors // Cancer. —
2010. — 116. — P. 4256-4265.
49. Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib
versus everolimus in advanced renal cell carcinoma
(METEOR): Final results from a randomised, openlabel,
phase 3 trial // Lancet Oncol. — 2016. — 17. —
P. 917-927.
50. Motzer R.J., Hutson T.E., Ren M. et al. Independent
assessment of lenvatinib plus everolimus in patients
with metastatic renal cell carcinoma // Lancet Oncol.
— 2016. — 17. — P. e4-e5.
Том 12, №4. 2021
51. Hutson T.E., Dutcus C.E., Ren M. et al. Subgroup
analyses and updated overall survival from the phase
II trial of lenvatinib (LEN), everolimus (EVE), and
LEN1EVE in metastatic renal cell carcinoma (mRCC) //
Abstract (4553) and poster (175) presented at the
Annual Meeting of the American Society of Clinical
Oncology; June 3–7, 2016; Chicago, IL.
52. Motzer R.J., Escudier B., Tomczak P. et al. Axitinib versus
sorafenib as second-line treatment for advanced renal
cell carcinoma: Overall survival analysis and updated
results from a randomised phase 3 trial // Lancet
Oncol. — 2013. — 14. — P. 552-562.
53. Escudier B.J., Powles T., Motzer R.J. et al. Efficacy of
cabozantinib (C) vs everolimus (E) in patients (pts)
with advanced renal cell carcinoma (RCC) and bone
metastases (mets) from the phase III METEOR study //
Abstract (4558) and poster (180) presented at the
Annual Meeting of the American Society of Clinical
Oncology; June 3–7, 2016; Chicago, IL.
54. Cella D., Escudier B., Powles T.B. et al. Quality of life
(QoL) in the phase 3 METEOR trial of cabozantinib vs
everolimus for advanced renal cell carcinoma (RCC) //
Abstract and poster (816P) presented at the Annual
Congress of the European Society for Medical Oncology;
October 7–11, 2016; Copenhagen, Denmark.
55. Carlo M.I., Feldman D.R. Response to nivolumab in a
patient with metastatic clear cell renal cell carcinoma
and end-stage renal disease on dialysis // Eur. Urol. —
2016. — 70. — P. 1082-1083.
56. Tabei T., Natsume I., Kobayashi K. Successful treatment
of metastatic clear cell carcinoma with nivolumab in a
patient receiving dialysis treatment // Int. J. Urol. —
2017. — 24. — P. 708-710.
57. Champiat S., Lambotte O., Barreau E. et al.
Management of immune checkpoint blockade
dysimmune toxicities: A collaborative position
paper // Ann Oncol. — 2016. — 27. — P. 559-574.
58. Alhamad T., Venkatachalam K., Linette G.P. et al.
Checkpoint inhibitors in kidney transplant recipients
and the potential risk of rejection // Am. J. Transplant.
— 2016. — 16. — P. 1332-1333.
59. Derosa L., Routy B., Enot D. et al. Impact of antibiotics
on outcome in patients with metastatic renal
cell carcinoma treated with immune checkpoint
inhibitors // Abstract (462) and poster (E1) presented
at the Annual Genitourinary Cancers Symposium of
the American Society of Clinical Oncology; February
16–18, 2017; Orlando, FL.
60. Singh H., Kim G., Maher V.E. et al. FDA subset analysis
of the safety of nivolumab in elderly patients with
advanced cancers // Abstract (10010) presented
at the Annual Meeting of the American Society of
Clinical Oncology; June 3–7, 2016; Chicago, IL.
61. McDermott D.F., Motzer R.J., Atkins M.B. et al. Longterm
overall survival with nivolumab in previously treated
patients with advanced renal cell carcinoma (aRCC)
from phase I and II studies // Abstract (4507) presented
at the Annual Meeting of the American Society of
Clinical Oncology; June 3–7, 2016; Chicago, IL.
50
Обзор литературы